Osteoporosis Treatment:When to Discontinue and When to Re-start

作     者：Silvano Adami Luca Idolazzi Elena Fracassi Davide Gatti Maurizio Rossini 

作者机构：Rheumatology UnitUniversityof Verona 

出 版 物：《Bone Research》 (骨研究（英文版）)

年 卷 期：2013年第1卷第4期

页      面：323-335页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：osteoporosis treatment bisphosphonates duration of osteoporosis treatment 

摘      要：A number of effective therapies for the treatment of osteoporosis have become available in recent years. However, uncertainty exists regarding their long-term use and effectiveness. Bisphosphonate treatment, unlike hormone replacement, denosumab or teriparatide, is associated with benefits extended even after treatment discontinuation. The extended benefits are most apparent for alendronate （ALN） and zoledronate （ZOL）. A drug holiday might be considered in patients compliant with treatment, and who have had a response fractures the decision to consider a drug holiday should treatment. at low-moderate risk and who have been fully to treatment. In patients at low-moderate risk of be balanced also with the safety profile of each